Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
Running, not enrolling · Phase 2
Conditions studied: Opioid Use Disorder (OUD)
In brief
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Key facts
- Study ID
- NCT04464980
- Run by
- NYU Langone Health
- People needed
- 1516
- Starts
- 2021-06-08
- Expected to finish
- 2027-01-31
- Last updated by the study team
- 2026-07-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST) — Little Rock, Arkansas, United States
- Tarzana Treatment Centers, Inc. — Tarzana, California, United States
- Liberation Programs, Inc. — Bridgeport, Connecticut, United States
- Operation PAR — Clearwater, Florida, United States
- Gateway Community Services — Jacksonville, Florida, United States
- Aspire Health Partners — Orlando, Florida, United States
- Mountain Manor / Maryland Treatment Centers — Baltimore, Maryland, United States
- McLean Hospital — Belmont, Massachusetts, United States
- Stanley Street Treatment and Resources, Inc. — Fall River, Massachusetts, United States
- Square Medical Group, LLC — Newton, Massachusetts, United States
- Gibson Center for Behavioral Change — Cape Girardeau, Missouri, United States
- Dartmouth Hitchcock - ATP — Lebanon, New Hampshire, United States
- University of New Mexico Addiction and Substance Abuse Program — Albuquerque, New Mexico, United States
- Bellevue Hospital Center — New York, New York, United States
- Adapt Integrated Health Care — Roseburg, Oregon, United States
- Adapt Integrated Health Care — Winston, Oregon, United States
- Center for Psychiatric and Chemical Dependency Services (CPCDS) — Pittsburgh, Pennsylvania, United States
- Internal Medicine Recovery Engagement Program (IM-REP) — Pittsburgh, Pennsylvania, United States
- Shoreline Behavioral Health Services — Conway, South Carolina, United States
- Huntsman Mental Health Institute / University of Utah — Salt Lake City, Utah, United States
- Chestnut Ridge Center — Morgantown, West Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.